Most people start Ozempic to lose weight. The growing body of research suggests the drug may be doing considerably more, including directly reducing systemic inflammation through mechanisms that operate independently of how much weight is lost. This emerging picture has implications for a broader range of patients than just those seeking to reduce body weight.
What the SELECT Trial Found About Inflammation
The SELECT trial is the landmark study that established Ozempic’s cardiovascular benefits in people without diabetes. Published in 2023 and updated with final results in 2026, it enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, but without type 2 diabetes.
Over a median of 33 months, participants on semaglutide experienced a 20 percent reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death, compared to placebo.
The inflammation findings within SELECT are equally striking. Semaglutide produced a 38 percent reduction in high-sensitivity CRP (hsCRP), a primary biomarker of systemic inflammation, compared to placebo. Critically, this reduction appeared early in the trial, before participants had lost substantial weight.
A prespecified subgroup analysis published in The Lancet in 2025 found that even among patients who lost less than 2 percent of body weight during the trial, semaglutide was associated with meaningful CRP reductions. This finding challenges the assumption that GLP-1 benefits are simply downstream of weight loss.
Ozempic’s Anti-Inflammatory Effect Independent of Weight Loss
The weight-independent inflammation data is one of the most scientifically interesting aspects of semaglutide research.
In standard obesity pharmacology, anti-inflammatory benefits are assumed to flow from fat reduction. Adipose tissue, particularly visceral fat around the organs, actively secretes pro-inflammatory cytokines, including TNF-alpha, IL-6, and CRP precursors. Reducing fat mass reduces this cytokine output, which lowers inflammation markers. This is the expected pathway.
What SELECT’s subgroup data suggests is that semaglutide has additional pathways that reduce inflammation directly, without requiring significant fat loss. The proposed mechanisms include:
GLP-1 receptor activation on immune cells. GLP-1 receptors are found on macrophages, T cells, and dendritic cells. When semaglutide activates these receptors, it shifts macrophages toward an anti-inflammatory (M2) phenotype and reduces inflammatory signaling in T cells.
NF-kB pathway inhibition. NF-kB is one of the central molecular switches that drives systemic inflammation. Several studies have found that GLP-1 receptor agonists suppress NF-kB activation, reducing downstream production of inflammatory cytokines.
Direct reduction of IL-6 and TNF-alpha. A 2024 systematic review and meta-analysis published in Frontiers in Cardiovascular Medicine confirmed that semaglutide reduces levels of IL-6 and TNF-alpha, two major pro-inflammatory cytokines, across multiple clinical trials.
CRP Reduction in Weight Loss Trials
The anti-inflammatory signal is not limited to the SELECT cardiovascular trial. Weight loss trials have documented similar CRP reductions.
In the STEP 1 trial, which enrolled adults with obesity (without established CVD), participants on semaglutide 2.4 mg experienced a 37.2 percent reduction in CRP at 68 weeks, compared to an 11.8 percent reduction in the placebo group. The magnitude of this difference is clinically significant: reducing hsCRP from a high-risk range (above 3.0 mg/L) into a lower-risk range has well-established associations with reduced cardiovascular event rates.
| Trial | CRP Reduction (Semaglutide) | CRP Reduction (Placebo) |
|---|---|---|
| SELECT (cardiovascular outcomes) | 38% | Not reported separately |
| STEP 1 (weight management) | 37.2% | 11.8% |
| SUSTAIN/PIONEER analyses | 25-40% | Variable |
What Conditions May Benefit from Semaglutide’s Anti-Inflammatory Effects?
Research is actively exploring GLP-1 effects in several inflammatory conditions. The current evidence ranges from clinical confirmation to preliminary signals.
Non-alcoholic fatty liver disease (NAFLD/NASH). Semaglutide has shown significant reductions in liver inflammation (steatohepatitis) and fibrosis in phase 2 trials. Phase 3 trials are ongoing. The anti-inflammatory mechanism in the liver is well-characterized.
Chronic kidney disease. Semaglutide was approved in 2024 for reducing kidney disease progression in patients with type 2 diabetes and CKD. Reduction of renal inflammation is part of the proposed mechanism, alongside hemodynamic effects.
Obstructive sleep apnea. A 2024 trial (SURMOUNT-OSA) found semaglutide reduced the severity of obstructive sleep apnea substantially, beyond what weight loss alone would predict, suggesting a direct effect on upper airway inflammation.
Neuroinflammation and neurodegenerative disease. GLP-1 receptors are present in the brain, and neuroinflammation is implicated in Alzheimer’s disease, Parkinson’s disease, and depression. Multiple clinical trials are currently running, including two large trials (EVOKE and EVOKE Plus) examining semaglutide specifically for Alzheimer’s disease. Results are expected in the coming years.
Rheumatoid arthritis and psoriasis. Case reports and small studies suggest benefit. No large randomized trials have been completed. These remain speculative but are areas of active interest.
What Ozempic Is Not
It is important to be precise about what the evidence shows and what it does not.
Ozempic is not an anti-inflammatory drug in the traditional classification. It is not approved for treating any inflammatory condition except as part of its cardiovascular indication. It does not work through the same pathways as NSAIDs, corticosteroids, or biologic immunosuppressants.
The anti-inflammatory effects documented in clinical trials are likely part of a broader metabolic reprogramming, rather than targeted suppression of specific inflammatory pathways. This means the effects are generally beneficial but are not a substitute for specific anti-inflammatory therapy in conditions like autoimmune disease.
Patients with inflammatory conditions who are also candidates for GLP-1 therapy for metabolic reasons may receive dual benefits. But the anti-inflammatory signal should not be the primary or sole justification for starting Ozempic in the absence of a metabolic or cardiovascular indication.
The Bottom Line on Ozempic and Inflammation
The evidence is clear that semaglutide reduces systemic inflammation markers substantially and that some of this effect is weight-independent. The SELECT trial’s cardiovascular benefit is likely partly mediated through this anti-inflammatory mechanism. The extension of this effect into neurological, hepatic, and renal contexts is an active and promising area of research.
For patients who have both a metabolic indication for GLP-1 therapy and an inflammatory condition, the overlap is worth discussing with their physician. For patients seeking to use Ozempic primarily as an anti-inflammatory agent without a metabolic or cardiovascular basis, the evidence does not currently support that use.